Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
49 hedge funds and large institutions have $259M invested in Adaptimmune Therapeutics in 2016 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 13 increasing their positions, 6 reducing their positions, and 12 closing their positions.
117% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 6
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
4% more capital invested
Capital invested by funds: $250M → $259M (+$9.01M)
0% more funds holding
Funds holding: 49 → 49 (0)
0% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$80.8M |
| 2 |
Millennium Management
New York
|
+$4.68M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.98M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$3.51M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$2.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$3.92M |
| 2 |
UBS AM
Chicago,
Illinois
|
-$2.55M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$1.7M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.57M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$1.31M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
Marshall Wace
London,
United Kingdom
| – | -$1.7M | -140,983 | Closed |
|
|
52
Point72 Asset Management
Stamford,
Connecticut
| – | -$1.57M | -130,200 | Closed |
|
|
GAMA
53
Graticule Asia Macro Advisors
New York
| – | -$603K | -50,000 | Closed |
|
|
AFM
54
Anson Funds Management
Dallas,
Texas
| – | -$371K | -30,737 | Closed |
|
|
QSS
55
Quantitative Systematic Strategies
Ponte Vedra Beach,
Florida
| – | -$303K | -24,918 | Closed |
|
56
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$131K | -10,844 | Closed |
|
57
UBS Group
Zurich,
Switzerland
| – | -$62K | -5,164 | Closed |
|
58
BlackRock
New York
| – | -$7K | -600 | Closed |
|
59
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$6K | -500 | Closed |
|
60
Citigroup
New York
| – | +$8 | +1 | New |
|
ADAP Hedge Fund Activity: Q1 2016 in Review
49 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q1 2016, worth a combined $259M — up 3.6% from $250M a quarter earlier.
Fund positioning in ADAP was balanced in Q1 2016: 12 funds opened new positions, 12 closed out, 13 added to existing stakes and 6 trimmed.
The largest buyer was NEA Management Company, opening a new position worth an estimated $80.8M. The largest seller was EverPoint Asset Management, exiting entirely with an estimated $3.92M sold.
- 49 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q1 2016, unchanged from Q4 2015.
- Funds reported $259M of Adaptimmune Therapeutics stock for Q1 2016, up 3.6% quarter-over-quarter.
- 12 funds opened new Adaptimmune Therapeutics positions in Q1 2016 and 12 closed out, a net change of 0 holders.
- The largest Adaptimmune Therapeutics buyer in Q1 2016 was NEA Management Company, an estimated $80.8M added.
- The largest Adaptimmune Therapeutics seller in Q1 2016 was EverPoint Asset Management, an estimated $3.92M sold.
Based on aggregated 13F filings for Q1 2016.